No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NKTX Nkarta
- 5.260
- -0.590-10.09%
Close Jul 2 16:00 ET
- 5.510
- +0.250+4.75%
Post 19:48 ET
370.66MMarket Cap-2238P/E (TTM)
5.890High5.245Low564.51KVolume5.780Open5.850Pre Close3.11MTurnover1.77%Turnover RatioLossP/E (Static)70.47MShares16.24052wk High0.78P/B167.81MFloat Cap1.28052wk Low--Dividend TTM31.90MShs Float79.160Historical High--Div YieldTTM11.03%Amplitude1.280Historical Low5.505Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $18
Stifel analyst Stephen Willey maintains $Nkarta(NKTX.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 40.8% and a total avera
Express News | Needham Reiterates Buy on Nkarta, Maintains $13 Price Target
William Blair Maintains Nkarta(NKTX.US) With Buy Rating
William Blair analyst Sami Corwin maintains $Nkarta(NKTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 35.3% and a total average return of -4.8% over the past ye
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $13
Needham analyst Gil Blum maintains $Nkarta(NKTX.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 38.6% and a total average re
H.C. Wainwright Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $23
H.C. Wainwright analyst Emily Bodnar maintains $Nkarta(NKTX.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 31.6% and a tota
Express News | Nkarta Initiates Ntrust-1 Of NKX019 In Lupus Nephritis, With First Patient In Screening. FDA Also Clears Second Investigational New Drug Application For NKX019 In Autoimmune Disease
Comments
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S(ASND.US$
$Vaxcyte(PCVX.US$
$Legend Biotech(LEGN.US$
$Janux Therapeutics(JANX.US$
$Aerovate(AVTE.US$
$Rhythm Pharmaceuticals(RYTM.US$
$Evolent Health(EVH.US$
$NewAmsterdam Pharma(NAMS.US$
$RxSight(RXST.US$
$TYRA BIOSCIENCES, INC.(TYRA.US$
$Edgewise Therapeutics(EWTX.US$
$4D Molecular Therapeutics(FDMT.US$
$Biogen(BIIB.US$
$PepGen(PEPG.US$
...
7
$Nkarta(NKTX.US$ jesus have some mercy
$Nkarta(NKTX.US$ Nkarta Prices Its Underwritten Offering Of 21M Shares At $10.00/Share And Pre-funded Warrants To Purchase 3M Shares At $9.9999/Warrant, With Gross Proceeds Of Approximately $240.1M
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg